Type 2 Diabetes Segment Bolsters Continuous Glucose Monitoring Device (CGMD) Market Growth

According to our new research study on "Continuous Glucose Monitoring Device (CGMD) Market Forecast to 2031 - Global Analysis - by Product, Application, Testing Sites, and End User", the market was valued at US$12.71 billion in 2024 and is projected to reach US$33.21 billion by 2031; it is estimated to register a CAGR of 14.9% during 2025-2031. The continuous glucose monitoring device (CGMD) market report emphasizes the trends prevalent in the global market and drivers and deterrents affecting its growth.

The rising global prevalence of diabetes, technological advancements in CGM devices, and benefits over conventional glucose monitoring contribute to the ever-increasing continuous glucose monitoring device (CGMD) market size. However, the high cost and limited reimbursement and user comfort and wearability challenges hamper the growth of the market. Further, integration with insulin delivery and AI-driven decision support will bring new continuous glucose monitoring device (CGMD) market trends in the coming years.

Growing Technological Advancements in CGM Devices Bolster Continuous glucose monitoring device (CGMD) Market Growth

Technological progress in continuous glucose monitoring (CGM) drives market growth by enhancing device accuracy, user experience, and expanding potential use cases. One of the most transformative improvements has been miniaturization. Modern CGM sensors, such as Abbott's Freestyle Libre 2 and Dexcom G6, are now coin-sized and significantly more discreet and comfortable to wear, facilitating closer user adoption in everyday life.

The Dexcom G7 exemplifies these gains with a 60% reduction in size compared to the G6 and includes an all-in-one sensor-transmitter design. It also features a shortened warm-up period of just 30 minutes (versus 2 hours) and enhanced alert settings, including up to a 12-hour grace period to replace the sensor, which collectively improve convenience and boost adherence. The G7 15-Day version, recently approved by the FDA, further extends wear time, offering around 15.5 days of continuous use and a slightly improved accuracy (MARD of 8.0%). Parallel developments from Abbott, such as the FreeStyle Libre 3, achieve an over 70% size reduction compared to previous models while maintaining a 14-day wear time and delivering continuous real-time glucose tracking (rt CGM).

The integration of AI-driven predictive algorithms marks another leap forward. Systems such as Medtronic's Guardian Sensor 4 can forecast glucose fluctuations up to 60 minutes ahead, enabling preemptive alerts and interventions. Broader industry trends indicate growing use of machine learning to model user-specific glucose trends, personalize alerts, and enhance interaction with other health data, pushing CGMs into truly predictive and personalized health tools.

Further bolstering this shift are emerging closed-loop "artificial pancreas" systems, which couple CGM devices with insulin pumps and intelligent algorithms to automate insulin dosing. Current hybrid systems still require manual meal boluses, but fully automated versions are actively under development, promising tighter glycemic control with less user input. CGMs are increasingly integrated into broader connected-health ecosystems, syncing with smartphones, smartwatches, and cloud platforms. This enables remote data sharing with healthcare providers, metabolic trend tracking, and composite health metrics such as combining glucose levels with heart rate or activity data.

Noninvasive CGM innovations are gaining ground. Research is exploring disruptive technologies such as optical sensors (e.g., Raman, near-infrared spectroscopy), electromagnetic-based glucose detection, and sweat-based or breath analyzers. Notable advances include a wearable watch with nanophotonic SPR technology that measures sweat glucose at sensitivities down to 0.12 mM, a novel electromagnetic, finger-joint sensor developed in India offering real-time glucose readings without any pricks and expected to retail under INR 500 (US$ 5.7). Although still early stages of development, these innovations signal a future where CGM could become entirely noninvasive.

These technological breakthroughs, notably in miniaturization, accuracy, wear time extension, AI-powered predictive analytics, artificial pancreas integration, device connectivity, and emerging noninvasive modalities, fundamentally reshape the CGM landscape. They are lowering barriers to adoption, enhancing patient convenience and clinical outcomes, and expanding CGMs into more personalized and preventive healthcare domains. Major innovations, including longer sensor wear times, miniaturized transmitters, improved accuracy, wireless connectivity, and integration with mobile apps and automated insulin delivery systems, continue to enhance CGM usability and patient outcomes, fueling rapid adoption. Therefore, the rising technological advancements in CGM devices propel the market growth.

The continuous glucose monitoring device (CGMD) market analysis has been carried out by considering the following segments: product, application, testing sites, and end user, and geography. Based on product, the continuous glucose monitoring device (CGMD) market is categorized into sensors, transmitters, and receivers. In 2024, the sensors segment held a significant continuous glucose monitoring device (CGMD) market share.

The market is segmented by application into type 1 diabetes and type 2 diabetes. The type 2 diabetes segment held the largest share of the continuous glucose monitoring device (CGMD) market in 2024 and is anticipated to register the highest CAGR during 2025-2031. Continuous glucose monitoring (CGM) is increasingly relevant for individuals with Type 2 diabetes (T2D), especially those managing complex treatment regimens or seeking improved glycemic control. As the broader diabetic population grows, currently evaluated at ~537 million adults globally, ~95% of diagnosed cases are Type 2, highlighting the clinical imperative for accessible CGM solutions, according to the International Diabetes Federation (IDF), 2024.

Recent product developments signal a strategic push to extend CGMs beyond their traditional dominion in insulin-dependent and Type 1 populations. For instance, in March 2024, Dexcom received FDA clearance for Stelo, a non-prescription CGM system specifically designed for people with Type 2 diabetes who don't require insulin. This OTC accessibility represents a significant milestone in making CGM technology more available and consumer-friendly. Supporting this shift, Dexcom's move to double down on the Type 2 market reflects recognition of significant upside: currently, only 7-8% of Americans with diabetes use CGMs. However, analysts expect usage to double within three years as insurance coverage evolves.

Financially, insurers are beginning to play a pivotal role. In 2023, UnitedHealthcare, one of the largest insurers in the US, started providing CGM coverage for Type 2 diabetes patients requiring insulin, greatly expanding access to the technology for this sizeable demographic. This shift has strong potential to accelerate adoption, reduce barriers, and improve outcomes among T2D patients. As coverage expands and devices become more accessible, Type 2 diabetes is poised to become a primary frontier in CGM adoption and innovation.

By testing sites, the market is categorized into fingertip testing and alternate site testing. The fingertip testing segment accounted for the largest share of the continuous glucose monitoring device (CGMD) market in 2024.

Regarding end user, the continuous glucose monitoring device (CGMD) market is segmented into hospitals and clinics, and self or homecare. The self or homecare segment held the largest continuous glucose monitoring device (CGMD) market share in 2024. The self-care or homecare is the fastest-growing segment of the CGM market, driven by rising diabetes prevalence, patient empowerment, and technological innovation. Technological innovation continues to fuel home care CGM adoption. The Dexcom G7, introduced in 2023, reduced device size by around 30 percent and enhanced accuracy by up to 20% compared to earlier models. Abbott's FreeStyle Libre 3, also new to market, offers a 14% size reduction and 12-15% accuracy improvement, enhancing patient comfort and compliance in self-use settings. Most next-generation CGMs now feature Bluetooth connectivity, enabling seamless integration with smartphones, smartwatches, and cloud-based platforms. This allows real-time feedback and data sharing via mobile apps, elevating usability for home users. Concurrently, AI and predictive analytics advancements are enhancing device responsiveness, helping users anticipate glucose trends and take timely actions.

The growth of telehealth and remote patient monitoring is closely linked to the use of continuous glucose monitors, as real-time glucose data facilitates virtual diabetes care. Studies have shown that remote CGM-guided management can match or even outperform in-person protocols in maintaining time-in-range, particularly under supervised virtual care frameworks. Cost remains a barrier, especially for those without insurance coverage, limiting access among lower-income patients. Regulatory inconsistency, varying approvals, and standards across jurisdictions complicate device adoption and distribution. Research indicates that up to 33% of data gaps occur during significant glucose excursions, and longer data lapses correlate with poorer glycemic control outcomes. Self-care and home care represent the dominant and most dynamic segments in the CGM market. The space benefits from strong product innovation, smaller, more accurate devices with mobile and AI-enabled capabilities, expanded payer coverage, and the normalization of remote care models.

Continuous Glucose Monitoring Device (CGMD) Market Share, by End User, 2024 (%)

Source: The Insight Partners Analysis

The geographic scope of the continuous glucose monitoring device (CGMD) market report includes assessing the market performance in North America, Europe, Asia Pacific, the Middle East and Africa, and South and Central America. North America is expected to dominate the market in 2024. The Continuous glucose monitoring device (CGMD) Market in North America is segmented into the US, Canada, and Mexico. The continuous glucose monitoring devices market in the US continues to evolve rapidly, driven by clinical innovation, expanding applications beyond traditional diabetes care, and growing attention to metabolic health. According to the Centers for Disease Control and Prevention (CDC), 2024, roughly 1 in 10 Americans live with diagnosed or undiagnosed diabetes. At the same time, prediabetes impacts over 100 million adults, factors that underpin sustained interest in CGM for managing glycemic control and guiding lifestyle interventions. CGMs are well established as the standard of care for Type 1 diabetes, with ~40-50% of individuals using them. Emerging evidence shows that CGM use among Type 2 diabetes patients, especially those not on intensive insulin, can help lower HbA1c, improve quality of life, and extend time-in-range, prompting discussions around broader adoption in primary care. Real-world usage data from Vanderbilt Medical Center (2021) reveal that most CGM users were under endocrinology care, had intensive insulin regimens, and had higher HbA1c values. However, a small but notable proportion, including ~12% not on any insulin, also use CGMs, highlighting shifting use patterns. Regulatory developments have broadened CGM access. In April 2025, the US Food and Drug Administration approved the Dexcom G7 15-Day system for adults, a more accurate device enabling up to 15.5 days of wear, with a grace period and automated correction bolus features expected to launch in the US in the latter half of 2025. Earlier, Dexcom's Stelo, the first over-the-counter CGM usable without a prescription and aimed at people with type 2 diabetes, garnered significant attention partly for democratizing glucose insights. Abbott followed suit with FDA clearances for two new CGM devices, Libre Rio for non-insulin-using Type 2 diabetics, and Lingo, targeting wellness and metabolism tracking, which offers both OTC, challenging the traditional prescription-only approach. The US CGM market transcends its roots in insulin-dependent diabetes to become a multifaceted ecosystem with expanded access through OTC and AI-enhanced wearables, new long-duration and implantable technologies, and evolving clinical use across primary and specialty care. While medical authority remains central, particularly for people with diabetes, the growing role of CGMs in metabolic wellness alongside emerging noninvasive technologies suggests a future in which real-time glucose visibility plays a routine, data-informed role in overall health management.

The continuous glucose monitoring device (CGMD) market in North America caters to consumers seeking to manage diabetes, and promote overall health and wellness through continuous glucose monitoring device (CGMD). Emerging technologies, AI-based sensors in CGMDs, and treatment effectiveness of the latest CGMDs, further enriching the continuous glucose monitoring device (CGMD) market.

Contact Us
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com